Dayforce, Scholar Rock, and More Stocks See Action From Activist Investors
Dayforce, Scholar Rock, and More Stocks See Action From Activist Investors Source link
Read more Dayforce, Scholar Rock, and More Stocks See Action From Activist InvestorsDayforce, Scholar Rock, and More Stocks See Action From Activist Investors Source link
Read more Dayforce, Scholar Rock, and More Stocks See Action From Activist InvestorsUpdated Dec 27, 2023, 7:34 am EST / Original Dec 27, 2023, 4:26 am EST Stock futures traded slightly lower Wednesday after the S&P 500 finished higher Tuesday and…
Read more Intel, Tesla, Apple, Iovance, NetEase, Coherus BioSciences, and More Stock Market MoversBristol Myers Squibb will acquire radiopharmaceutical therapeutics company RayzeBio for $62.50 a share in cash. Continue reading this article with a Barron’s subscription. View Options Source link
Read more Bristol Myers to Acquire RayzeBio in Deal Valued at $4.1 BillionTwo weeks ago, bluebird bio secured Food and Drug Administration approval for its gene therapy for sickle cell disease, a significant milestone for the roughly 100,000 people in…
Read more Bluebird Bio Stock Is in Free FallDec 19, 2023, 4:31 am EST Stock futures traded flat Tuesday, a day after the S&P 500 finished up 0.5% and moved closer to its all-time. The broad…
Read more Alphabet, Heico, Bluebird Bio, Plug Power, UBS, FedEx, and More Stock Market MoversStock futures pointed higher Friday as Wall Street returned for a shortened trading session following the Thanksgiving holiday. Retailers will be in focus on Black Friday, which marks…
Read more Walmart, Nvidia, Novo Nordisk, Vista Outdoor, GM, and More Stock Market MoversThese Stocks Are Moving the Most Today: Plug Power, Trade Desk, Doximity, Unity Software, Illumina, Wynn, and More Source link
Read more Plug Power, Trade Desk, Doximity, Unity Software, Illumina, Wynn, and More Stock Market MoversArdelyx Inc. ARDX, -0.58% on Tuesday won its long fight for U.S. regulatory approval of a treatment designed to help patients with chronic kidney disease. The biopharma company…
Read more Ardelyx wins long battle for FDA approval of kidney-disease treatmentUpdated Oct. 17, 2023 2:47 am ET Lonza Group warned that its profitability will take a hit next year from losing revenue from an agreement with Moderna and…
Read more Lonza Warns on 2024 Profitability Hit From Lost Moderna RevenueThis copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers visit http://www.djreprints.com. https://www.barrons.com/articles/stock-market-movers-8c0c7b23 Updated Sept. 19, 2023…
Read more NIO, Moderna, Block, U.S. Steel, and More Stock Market MoversThe Food and Drug Administration late Friday approved the first-ever pill that can be taken at home for postpartum depression. The medication, called zuranolone, and jointly developed by…
Read more FDA approves first-ever pill for postpartum depression in new mothersThis copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers visit http://www.djreprints.com. https://www.barrons.com/articles/solaredge-stock-guidanceprice-solar-e54cc9fb Updated Aug. 2, 2023…
Read more SolarEdge Stock Sinks After Weak Guidance. Why Analysts Are Still Upbeat.Pfizer Stock Gains After Earnings Beat. Revenue and Outlook Aren’t So Good. Source link
Read more Pfizer Earnings Beat. Guidance Disappoints.This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers visit http://www.djreprints.com. https://www.barrons.com/articles/stock-market-movers-fb3791aa Updated June 20, 2023…
Read more Alibaba, Dice, Arcellx, Avis, PayPal, and More Stock Market MoversIllumina CEO Francis deSouza Resigns Amid Regulatory Hurdles, Proxy Fight Source link
Read more Illumina CEO Francis deSouza Resigns Amid Regulatory Hurdles, Proxy FightBy Anthony O. Goriainoff AstraZeneca said Thursday that its and MSD’s Lynparza cancer treatment had been approved in the U.S. for the treatment of metastatic castration-resistant prostate cancer,…
Read more AstraZeneca Says US Approved Lynparza as a Prostate Cancer TreatmentThis copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers visit http://www.djreprints.com. https://www.barrons.com/articles/first-solar-stock-buying-solar-tech-firm-evolar-da85f0b1 Updated May 12, 2023…
Read more First Solar Stock Surges on Deal for European Solar Tech FirmPfizer Agrees to Buy Seagen for $43 Billion Source link
Read more Pfizer Agrees to Buy Seagen for $43 BillionNearly two years after biotechnology stocks began to tumble, executives at small and midsize companies in the space are finally accepting that share prices aren’t bouncing back anytime…
Read more Tanking Biotech Stocks Will Mean a Big Year for Deals. Who Could Benefit.